---
schema_version: "secwatch.filing_event.v1"
accession: "0000950103-25-003637"
form_type: "8-K"
ticker: "PGEN"
cik: "0001356090"
company_name: "PRECIGEN, INC."
filed_at: "2025-03-19T23:59:59+00:00"
generated_at: "2026-05-24T11:35:52.147954+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Precigen reports FY2024 net loss of $126M; FDA priority review for PRGN-2012 BLA

## Summary
- FDA accepted BLA for PRGN-2012 with priority review; PDUFA target date Aug 27, 2025.
- Pivotal study: 51% complete response (no surgeries), durable beyond 12 months (median 24 months).
- FY2024 net loss $126.2M ($0.47/share) vs $95.9M in 2023; revenue down 37% to $3.9M.
- Cash, equivalents, investments $97.9M; runway extended into 2026 beyond potential launch.
- Raised $87.5M in Dec 2024 from convertible preferred stock ($79M) and IP/royalty sale ($8.5M).

## SEC filing metadata
- accession: 0000950103-25-003637
- form_type: 8-K
- ticker: PGEN
- cik: 0001356090
- company_name: PRECIGEN, INC.
- filed_at: 2025-03-19T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1356090/000095010325003637/0000950103-25-003637-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1356090/000095010325003637/dp226512_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950103-25-003637
- JSON: https://secwatch.observer/filing/0000950103-25-003637.json
- Plain text: https://secwatch.observer/filing/0000950103-25-003637.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.